Piper "Regulatory News Bodes Well for Commercial Success; Upgrading to Overweight. Raising Target from $5 to $19. Adding Alzhheimers revenues. IP looks solid"
Increasing PDP projections on favorable uptake outlook. We are increasing our peak penetration rates for pima' in PDP due to what we anticipate will be greater clinical acceptance signaled both by the strong data presented at AA, our KOL diligence, as well as the FDA's apparent positive view on the safety and efficacy. We are advancing our launch date from 2016 to 2015 and increasing our peak penetration in patients with psycosis from 14% to 24% in the U.S. and from 10% to 18% in Europe